Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety of Oral Apixaban (Eliquis) Versus Subcutaneous Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy; a Prospective Randomized Open Blinded End-point (PROBE) Design

NCT02366871 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT02366871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02366871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety of Oral Apixaban (Eliquis) Versus Subcutaneous Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy; a Prospective Randomized Open Blinded End-point (PROBE) Design
Lead sponsor
University of Colorado, Denver
Phase
Phase 2
Overall status
Completed
Start date
April 28, 2015
Completion date
June 30, 2019
Enrollment
400 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

gynecologic cancer, venous thromboembolism